Neurocrine Biosciences Inc (NBIX) is a publicly traded Healthcare sector company. As of July 13, 2026, NBIX trades at $174.71 with a market cap of $17.81B and a P/E ratio of 26.56. NBIX moved -2.44% today. Year to date, NBIX is +25.65%; over the trailing twelve months it is +31.27%. Its 52-week range spans $84.23 to $181.18. Analyst consensus is strong buy with an average price target of $199.11. Rallies surfaces NBIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for NBIX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $174.71 |
| Market Cap | $17.81B |
| P/E Ratio | 26.56 |
| EPS | $6.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $181.18 |
| 52-Week Low | $84.23 |
| Volume | 243.37K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.10B |
| Net Income | $668.60M |
| Gross Margin | 98.17% |
22 analysts cover NBIX: 0 strong buy, 19 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $199.11.